COVID-19 -- Afghanistan
Abstract
--------
Background
Severe coronavirus disease 2019 (COVID-19) is associated with dysregulated inflammation. The effects of combination treatment with baricitinib, a Janus kinase inhibitor, plus remdesivir are not known.
Methods
We conducted a double-blind, randomized, placebo-controlled trial evaluating baricitinib plus remdesivir in hospitalized adults with COVID-19. All the patients received remdesivir (10 days or less) and either baricitinib (14 days or less) or placebo
Read more about it at HealthMap Global Disease Alerts via http://healthmap.org/ln.php?8016168&promed&0
No comments:
Post a Comment